Literature DB >> 1586250

Nervous system disease, immunological features, and HLA phenotype in Sjögren's syndrome.

A Hietaharju1, M Korpela, J Ilonen, H Frey.   

Abstract

Twenty seven patients with primary or possible Sjögren's syndrome with neurological manifestations were compared immunologically with 21 patients with Sjögren's syndrome with an intact nervous system. Patients with Sjögren's syndrome were divided into seropositive and seronegative subgroups with respect to the occurrence of one or more autoantibodies (antinuclear antibodies, rheumatoid factor, antibodies to SS-B) in their serum samples. This study of 48 patients indicates that the spectrum of nervous system disease in seronegative and seropositive subgroups is almost indistinguishable. No significant differences were found in the occurrence of circulating immune complexes, the levels of serum complement C3 and C4, or serum IgA, IgM, and beta 2 microglobulin with respect to the neurological manifestations. The serum IgG level, however, was significantly higher in the patients with Sjögren's syndrome with intact nervous systems than in those with neurological manifestations. No significant association was found between the HLA phenotype and nervous system disease. The occurrence of HLA-B8 and DR3 antigens was, however, significantly higher in those patients with antibodies to SS-B than in those without. This finding supports the suggestion that HLA-B8/DR3 may modulate autoantibody responses rather than disease expression in Sjögren's syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586250      PMCID: PMC1004702          DOI: 10.1136/ard.51.4.506

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  31 in total

1.  Late-life myopathy occurring with Sjogren's syndrome.

Authors:  D H SILBERBERG; D A DRACHMAN
Journal:  Arch Neurol       Date:  1962-06

2.  Neurologic complications of Sjogren's syndrome.

Authors:  W ATTWOOD; C M POSER
Journal:  Neurology       Date:  1961-12       Impact factor: 9.910

3.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

4.  Interstitial nephritis in Sjögren's syndrome.

Authors:  W H Tu; M A Shearn; J C Lee; J Hopper
Journal:  Ann Intern Med       Date:  1968-12       Impact factor: 25.391

5.  Evaluation of a quantitative immunoturbidimetric assay for rheumatoid factors.

Authors:  L M Melamies; H M Ruutsalo; H Nissilä
Journal:  Clin Chem       Date:  1986-10       Impact factor: 8.327

6.  Reversal of chronic polymyositis following intravenous immune serum globulin therapy.

Authors:  C M Roifman; F M Schaffer; S E Wachsmuth; G Murphy; E W Gelfand
Journal:  JAMA       Date:  1987 Jul 24-31       Impact factor: 56.272

7.  Primary Sjögren's syndrome with central nervous system disease mimicking multiple sclerosis.

Authors:  E L Alexander; K Malinow; J E Lejewski; M S Jerdan; T T Provost; G E Alexander
Journal:  Ann Intern Med       Date:  1986-03       Impact factor: 25.391

8.  The spectrum of neurological involvement in Sjögren's syndrome.

Authors:  A P Andonopoulos; G Lagos; A A Drosos; H M Moutsopoulos
Journal:  Br J Rheumatol       Date:  1990-02

Review 9.  Invited review: peripheral neuropathy in Sjogren's syndrome.

Authors:  J G Kaplan; R Rosenberg; E Reinitz; S Buchbinder; H H Schaumburg
Journal:  Muscle Nerve       Date:  1990-07       Impact factor: 3.217

10.  Primary Sjögren's syndrome in men. Clinical, serologic, and immunogenetic features.

Authors:  R Molina; T T Provost; F C Arnett; W B Bias; M C Hochberg; R W Wilson; E L Alexander
Journal:  Am J Med       Date:  1986-01       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.